Substructural QSAR approaches and topological pharmacophores. by Franke, R et al.
Environmental Health Perspectives
Vol. 61, pp. 239-255, 1985
Substructural QSAR Approaches and
Topological Pharmacophores
by Rainer Franke*, Stefan Huebel* and W. Juergen Streich*
For large and diverse data sets, simple QSAR methods based on linear and additive models can no longer
be applied. In such cases topological methods using descriptors directly derivable from two-dimensional
chemical structures provide a useful alternative. The results of such analyses can be used for lead optim-
ization, to guide biological testing and even aid in the design of novel compounds. Various types of
topological descriptors and algorithms are briefly discussed. Which of those is to be selected depends on
the objective of the investigation and the properties of the data set. Two new methods, LOGANA and
LOCON, are discussed in some more detail. With the help of these methods, substructural patterns ("to-
pological pharmacophores") characteristic of compounds possessing a certain biological property can be
evaluated. Both methods are designed in such away that full use can be made ofthe data handling capacity
of computers while maintaining an optimal impact of the experience of the researcher. They are model-
free and do not require any mathematical knowledge. While LOGANA deals with semiquantitative or even
qualitative biological data, LOCON can be applied to activity data on a continuous scale. The basic
procedure in both cases consists in the stepwise combination of substructural descriptors by the logical
operations "and," "or" and "not." With a simple example the utility of the methods is demonstrated.
Introduction
Quantitative structure-activity relationships (QSARs)
have become an indispensable tool to rationalize the
interaction of chemical compounds with living matter.
The basic philosophy ofQSAR methods is to draw con-
clusions by analogy assuming that similarity of drugs
with respect to certain chemical properties will result
in similar biological responses. The problem, then, is to
determine what these properties are and how they are
connected with the biological activity ofinterest. Tothis
end a set ofcompounds with known biological activities
(which will be called a "training series" throughout this
paper) is analyzed. The principal steps are always
roughly the same. First, a set of chemical descriptors
is selected so that all chemical properties of the com-
pounds that may be important for their biological action
are believed to be adequately characterized. The values
of all these descriptors are then collected or evaluated
for all compounds of the training series and fed into a
computertogether with the corresponding biological ac-
tivity data. The computer compares and connects the
descriptors and activities by means of a suitable algo-
rithm until a QSAR is found. In the broadest sense, a
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QSAR may be regarded as a computer-derived rule
which quantitatively describes biological activity in terms
of chemical descriptors. Once a QSAR is known, the
following may become possible: conclusions and hy-
potheses as to molecular mechanisms of action; optim-
izations of a given lead compound that includes
maximizing desired and minimizing undesired (e.g.,
toxic) biological effects; prediction of what kind of bio-
logical activity a new or as yet untested compound is
likely to possess (which may aid in the preselection of
compounds for screening programs in order to increase
the incidence of actives, but also in recognizing poten-
tially toxic chemicals); generation of new lead
compounds.
Different approaches (and data sets) are required de-
pending on which ofthe above objectives is in the fore-
ground. A variety of QSAR methods has, in fact, been
developed during the last years not only for this reason
but also since the data to be handled may be very dif-
ferent. The training series, for example, can largely
vary in size and with respect to the complexity or di-
versity of chemical structure variation. Biological ac-
tivity data, on the other hand, may come from very
different sources or tests and be expressed on many
different scales. Thus, a whole tool box of methods for
both the evaluation of descriptors as well as the appli-
cation of computer algorithms is necessary to be able
to cope with the many possible situations (1-15).FRANKE, HUEBEL, AND STREICH
In, this paper we wish to deal with the use of topol-
ogical (substructural) descriptors in QSAR work. After
a short review of currently used substructural ap-
proaches two new techniques for the evaluation of to-
pological activity patterns, LOGANA and LOGON, will
be discussed in more detail and illustrated with a simple
example.
Why Topological Descriptors?
The most popular and widely used QSAR method
these days certainly is the Hansch approach. Its prin-
ciple consists in correlating the logarithm of biological
activity (logA) with hydrophobic, electronic, and steric
molecular parameters by means of linear multiple
regression analysis. The result is equations in which log
A as dependent variable is expressed by a weighted
linear combination of those molecular parameters that
turn out to make a statistically significant contribution
to "explaining" the variance of log A in the training
series. This approach requires precise enough biological
activity data on a continuous scale, the applicability of
linear free energy relationships that are based on a sim-
ple linear and additive model, and the availability ofthe
respective molecular parameters for all structural var-
iants in the training series. Usually, the latter condi-
tions are only fulfilled in so-called congeneric series where
at a constant parent structure only substituents are
varied. Buteventhere themodelassumptions ofHansch
analysis may break down if the substituent exchanges
alterthe structure too drastically (16), andfortooexotic
substituents appropriate parameters may not be avail-
able. One cannot but admire the ingenuity with which
especially the Hansch group has pushed this type of
analysis almost beyond its limits handling training se-
ries with several hundreds of compounds and partly
very diverse structures in one analysis. In order to be
abletodothat, however, so-called "indicatorordummy"
variables frequently become necessary in order to char-
acterize structural variations that cannot adequately be
accounted for by physicochemical parameters. These
indicator variables are binary quantities usually de-
scribing the presence or absence of certain structural
features according to
1,
xii=
09
if the ith feature
is present in the
jth compound
if not
In that sense, they already represent the simplest case
oftopological descriptors since they are directly derived
from the topology (two-dimensional chemical formula)
of the compounds under consideration.
QSAR equations containing both, terms with physi-
cochemical and with indicator variables, represent a
mixedformofthe Hanschapproachandthe Free-Wilson
analysis (1,4,7,11,15). The two methods are formally
equivalent since, in both instances, the logarithm of
biological activity is built up additively on the basis of
a linear model from contributions of the substituents.
The difference is that the Free-Wilson analysis does not
require physicochemical molecule parameters but is en-
tirely based on topological descriptors according to the
model
log A, = >,xiz, + IL (2)
where A, is the biological activity ofthej-th compound,
xi is a topological descriptor according to Eq. (1) de-
scribing the absence or presence ofthe i-th substituent
variable (which, in this case, includes type and position
ofsubstituent), z;the contribution ofthei-thsubstituent
variant to logAi, and ,u is the contribution ofa constant
parent moiety. Free-Wilson and Hansch analyses sup-
plement each other in that the former is particularly
suitable incases whererelatively fewsubstituents occur
in many positions of substitution while the domain of
the latter is where many substituents are varied in only
few positions. The applicability ofFree-Wilson analysis
can be extended by introducing terms to account for
intramolecular interactions (15) or by including fusion
points orheteroatoms, etc., as variables (17). However,
both Free-Wilson and Hansch analyses will break down
or cannot be applied in either ofthe following cases: the
biological measurements available are only semiquan-
titative or qualitative; or the structural changes in the
startingset are so drastic thatthe linearmodel onwhich
both methods are based is no longer valid. Ifstructural
variations become tooextensive inreally heterogeneous
andlarge datasets one hasto lookforotherpossibilities.
One way to go could be the application of molecular
modeling techniques combined with interactive com-
puter graphics. These methods, however, need precise
biologicalinformationlargelyfreefrompharmacokinetic
contributions and cannot be applied to large data sets.
In addition, a certain amount ofapriori knowledge and
a hypothesis to start with are usually required. This
brings us back to topological descriptors which are easy
to derive for any structure but must, of course be de-
fined in a much more general framework than for Free-
Wilson analysis to be able to cope with very diverse
structures. Such problems may arise much more fre-
quently than is commonly believed. Typical cases are
where data from large data bases, from mass screening
or data collections from literature are to be analyzed.
Topological (Substructural)
Descriptors
For a better understanding of the following, a defi-
nition of how the termsfeature and descriptor will be
used throughout this paper seems appropriate. We will
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call topological features any two-dimensional fragment
ofchemical compounds used to characterize their struc-
ture in a topological analysis. Topological descriptors
then describe the occurrence of such features in each
compound. In the case of Free-Wilson analysis, for ex-
ample, a feature is a particular substituent in a defined
position ofsubstitution, and the corresponding descrip-
torisdefined accordingto Eq. (1). Therearemanytypes
oftopological descriptors which all have in commonthat
they can directly be derived either from two-dimen-
sional chemical structures or from connection tables;
excellent reviews arepresented, forexample, by Stuper
et al. (8) and by Bawden (18). The simplest possible
descriptors are counts of atoms or bonds of specified
types which, however, contain very little information
about the topology of molecules so that completely dif-
ferent molecules may have identical descriptor values.
For this reason such descriptors will not be discussed
here although they have occasionally been applied in
QSAR analysis (18).
Part of the structural information lost in the simple
atom and bond descriptors can be restored ifmore com-
plex features comprising larger parts ofchemical struc-
tures (substructures) are considered. There are several
ways of doing that. First of all, features can be gen-
erated following certain rules algorithmically starting
from single atoms or bonds as centers leading to atom-
centered andbond-centered fragments. Such fragments
are defined in terms of concentric areas of structure
surrounding each atom (except hydrogens) or bond at
different levels ofcomplexity and specificity with infor-
mation about atom and bond types, nonhydrogen con-
nections, etc., in this area. Very commonly used are
the so-called augmented atom fragments that describe
atoms with their next neighbors. In derivingthese frag-
ments, each nonhydrogen nonterminal atomis once con-
sidered as a center. Augmented atom fragments may
be further extended by enlarging the area considered.
Ganglia-augmented atom fragments, for example, are
obtained ifthe additional bonds on all atoms are added
to an augmented atom fragment. The set of features
generated depends on the structures present in the
training series. Problems of redundancy may arise if
features of different complexity are to be used in the
same analysis.
Another possibility is to define a library of features
(substructures) insuchawaythatbasictopologicalchar-
acteristics are adequately represented. Such character-
istics can be, for example, rings, functional groups,
heteroatoms or other centers believed to be important
for drug-biosystem interaction and distances between
such centers (paths). Although linear notations as used
for computer storage and retrieval of chemical struc-
tures, e.g., WLN (19), can serve as a source offragment
codes of this type, it seems advisable to select a more
problemoriented libraryonthebasisof"common sense"
and the experience ofthe researcher (20). According to
Kirschner and Kowalski (21) such a library should in-
clude features that "arethoughttoprovide atleastsome
information related to the biological activity, are known
for the greatest majority ofthe compounds and iffound
to be related to activity, will provide the chemist with
some degree of insight into the mechanism of action."
To this end a basic library of potentially active centers
such as atoms or groups of atoms (functional groups)
likely to be involved in drug-receptor interaction via
van der Waals or other forces may be set up and used
to create the concrete features for each particular prob-
lemviaa set ofrules (alanguage) in an open-ended way.
Cases in point are the SSFN and the DCAM systems
that are based on the predefined "descriptor centers"
and distances between them (22-24).
Even with more or less complex substructural fea-
tures, a considerable part of structural information is
still lost. This situation may be overcome in either of
two ways. Following the approach of Jurs and col-
leagues (8) additional descriptors can be defined that
characterize the environment ofthe substructures (en-
vironment descriptors). A better strategy is to code not
only for the type of substructures but also for the mo-
lecular region where they occur whenever this is fea-
sible. A typical example is Free-Wilson analysis which,
however, is restricted to more orless congeneric series.
For more heterogeneous data sets more general tem-
plate models become necessary. A template can be gen-
erated by superimposing all structures of the starting
set in such a way that all features of these structures
considered as potentially important (descriptors cen-
ters) are unambiguously and adequately represented.
As a result an artificial reference diagram is obtained
that may be considered as a hypothetical parent of all
compounds. Descriptors are then derived by comparing
the structure ofeachcompoundwiththistemplate. Such
approaches have, forexample, beenusedbyCammarata
and Menon (25,26) by Henry and Block (27,28), and in
ourlaboratory (15,29-32); philosophically, they are sim-
ilar with the "hyperstructure" of the DARC/PELCO
system (33) and of the MTD approach of Simon and
Colleagues (34).
Once the features are defined each compound is char-
acterized by a set (a vector) of descriptor values (one
foreachfeature). Thesimplestwaytodefine suchvalues
is that according to Eq. (1), which is particularly suit-
able for complex template approaches and is also used
in the methods LOGANA and LOCON to be discussed
later. The descriptor values may also be defined as oc-
currence numbers ofthe features in the compounds ac-
cording to
xij =
4
k, if feature i
occurs k times in
thejth compound
(3)
0, if feature i is
not present in the
jth compound
241FRANKE, HUEBEL, AND STREICH
Finally, a third possibility is to derive descriptors on
the basis of graph theory or pragmatic rules. An ex-
ample of the first type is molecular connectivity (35),
and ofthe latter type, are the environment descriptors
ofJurs (8).
Incertaintypes ofanalysis topologicaldescriptors are
used together with some physicochemical parameters
as, for example, molar refractivity or log P. This can
be advantageous in treating complex problems but has
the danger that the interpretation of the results may
become extremely difficult due to complicated relation-
ships between the two descriptor sets. As willbe shown
later, physicochemical quantities can also be trans-
formed into binary variables.
Usingtopological descriptors one is, ofcourse, asking
less of the data than with, for example, extrathermo-
dynamic parameters, but such descriptors are the only
possibility for large data sets of high structural diver-
sity, and the results can still effectively be used for
guidingsynthesis andbiologicaltesting. Thecrucialstep
always is the selection of features. If the features are
in error no meaningful results can be expected. Inmany
cases this implies that compromises have to be made
and that different types offeatures must be used in the
same analysis. There are a number of problems that
may arise when defining the features such as redun-
dancy or ambiguity. These problems, however, are so
special and complicated that they cannot be discussed
here.
Principles of Topological Analysis
There are many possible ways to look for relations
between topological descriptors and biological proper-
ties (classical QSAR methods where topology-derived
descriptors such asindicator variables ormolecular con-
nectivity are used will not be considered here). There
are usually two objectives: to recognize substructures
"typical" of a particular biological effect and to predict
for new compounds whether they will be (highly) active
with respect to this effect. Which of the two is in the
foreground depends onthe data set, the descriptors and
the procedure used. It may be said, however, that most
ofthe procedures so far described in the literature per-
form better with respect to the latter; exceptions are
the methods LOGANA and LOCON to be discussed in
thispaperwhichwereespeciallydesignedforevaluating
"topological pharmacophores."
From a methodological point of view three types of
approaches may be differentiated:* heuristic "activity
index" techniques; classification (pattern recognition)
methods; and topological pattern finders. This differ-
entiation is not very sharp (especially not between the
*There are some applications where substructural features as de-
scribed in the preceding section are used as variables in multiple
regression analysis (17,36,37). This again implies at least in part that
a linear additive model is supposed to hold which will be an exception
rather than a rule. For this reason approaches of this type will not
be discussed here.
first two categories) but helpful to systematize the var-
ious procedures.
Heuristic index techniques start from a classification
ofthe compounds ofthe training series with respect to
the biological activity of interest (usually, two classes,
active versus inactive compounds, are used). The dis-
tribution ofthe selected features overtheclassesisthen
analyzed, and based on frequencies and/or probabilities
of occurrence each feature is assigned an "activity in-
dex" which expresses how important it is for the active
class. New compounds are then classified by summing
the indices oftheir features. A typical approach ofthis
kind is the substructural analysis introduced by Cramer
et al. (38), which represents the first large scale com-
puterized method for topological analysis. The com-
pounds ofatrainingseries were divided into two classes
(active and inactive) and fragmented into substructures
usingalibrary ofatom, bond and substructure features.
For each feature the so-called substructure activity fre-
quency (SAF) is then calculated according to:
SAFi =
number of active compounds containing the feature i
total number of compounds containing the feature i
(4)
The SAFi value embodies the probability contribution
of the i-th feature to the overall probability that the
compound containing that feature will be biologically
active. To characterize the activity of compounds the
mean substructure activity frequency (MSAF) is used.
For thej-th compound this value is
MSAF, = -E xiSAF(
where m,isthenumberoffeatures(fragments occurring
in the j-th compound and xii a topological descriptor
defined according to Eq. (2). As shown by an example
concerning the immunoregulatory potency of 770 com-
pounds, the MSAF values are indeed connected with
biological potency so that the probability ofa compound
being active will be the higher the higher its MSAF
value is. An unequivocal classification of compounds
simply by means ofMSAF values, however, is not pos-
sible since for that purpose a decision rule would be
required.
Statistically more sophisticated is the approach of
Hodes and colleagues (39-42) who devised a heuristic
method for the automated selection of drugs for anti-
tumor screening with the objective of increasing the
incidence of biologically active compounds. Again, the
compounds of a training series are divided into two
classes (active/inactive) and described by a library of
topologicalfeatures (ring, nucleus, augmented atomand
ganglion augmented atom fragments). Each fragment
isthentested to determine whetheritsincidence inboth
classes is significantly different from the randomly ex-
pected incidence. A particular feature i will gain in im-
portance for the class considered as this difference
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becomes larger, and this may be expressed by the re-
ciprocal ofthe probability Pi that this difference can be
generated by chance. On this basis, an activity index
Ii,a, and an inactivity index Ii,in can be defined for each
feature i.
Ii,a = l/Pi,a (6)
Ii,in = 1/Pi,in (7)
For any given compound X with fragments i = 1,...
n, an activity and an inactivity score can now be com-
puted by simply multiplying the respective Ii,a or Ii,in
values. On numerical grounds, it is desirable to perform
a logarithmic transformation and to define these scores
as
n
IX,a=> log Ii,a (8)
i=l1
n
x,in log Ii,in (9)
The scores provide a measure of the probabilities that
compound X will belong to the respective classes. If
potentially active compounds are to be selected for a
screening program, both the activity as well as the in-
activity score have to be taken into account, which can
be done in various ways depending on the needs ofthe
selection program. A very simple way is to combine
both scores into a single quantity such that higher val-
ues establish high priorities for testing. An extended
version ofthis procedure has successfully been applied
to mutagenicity data by Tinker as a predictive test for
hazard evaluation (43,44). Philosophically similar is the
ORACLE procedure (22,24), which was developed for
the purpose ofguiding the screening ofcompounds in a
battery of biological tests. The basis of ORACLE is a
structure and pharmacological activity file including
about 6000 compounds and 55 major types of pharma-
cological activities. The compounds of the data file are
divided into 55 classes according to the types of their
biological activity. Each class is then separately com-
pared with the rest of the compounds contained in the
remaining54classesinordertofinddescriptors (derived
from SSFN; see above) that represent the particular
type of activity exhibited by the class under investi-
gation. A descriptor is considered to represent a par-
ticular activity feature ifits presence in this class is not
achance event. Sets ofdescriptors are found inthis way
which are regarded to be typical ofeach respective class.
Once these sets are known, the type ofpharmacological
activity to be expected for a new compound can be pre-
dicted so that it becomes possible to decide what com-
pound should be investigated for which of the 55
pharmacological effects. The method will fail if a phar-
macological effect can be produced via different mech-
anisms of action. Nevertheless, ORACLE has
successfully been applied. The system correctly rec-
ognized the presence ofearlierestablished activities for
the majority ofcompounds in the data base, and a num-
ber ofunknown activities could be predicted for several
compounds.
Another program ofthe index type which, however,
is already very close to classification techniques is the
STRAC procedure designed for lead optimization (22).
Again, the compounds of the starting set are divided
into the classes "active" and "inactive" and described
by topological features. These features are selected as
in Free-Wilson analysis as substituents in their position
ofsubstitution so that STRAC is limited to more or less
homologous series. The advantage over the Free-Wil-
son analysis is that no assumptions about the additivity
ofsubstituent effects are required. A feature is consid-
ered discriminating if the probability that a compound
containing this feature belongs to one ofthe two classes
is greater than a certain threshhold value. In many
cases the discriminating features found in this way are
not sufficient to classify all compounds of the training
series. New discriminating features are then derived
by logical operations in an interactive process until a
sufficient separation ofthe two classes is achieved. The
features so obtained are either typical for the active
("activity features") or for the inactive ("inactivity fea-
tures") analogs. New compounds can then be classified
according to their predominant features. A compound
is rated active if
and inactive if V.
- Vin > -q
Vij
- Va. > q
(10)
(11)
where Va and Vi,, are the occurrence numbers ofactivity
and inactivity features, respectively, in this compound
and -9 is a certain threshold value.
Methods of the second category, classification tech-
niques, also start from a classification ofthe compounds
ofthe training series but use different strategies as the
index approaches. There is a variety of methods avail-
able which will not be discussed here in detail
(8,11,15,21). The principle usually is to find a classifier
that is a mathematical expression containing the de-
scriptors as variables. In most (but not all) cases such
classifiers are weighted linear combinations ofvariables
that are found to make a significant contribution to class
separation. With the help ofthe classifiers and decision
rules that can be based on statistical or geometrical
(distances in parameter space) criteria, the activity of
newcompounds canbepredicted. Themethodsofchoice
for topological descriptors are the so-called "nonprob-
abilistic" or "non-parametric" techniques such as, for
example, the linear learning machine or the k-nearest-
neighbors method, since these methods do not require
certain statistical data distributions that are not likely
to be fulfilled for such variables. Both index as well as
classification methodsmaketheimplicitassumptionthat
the contribution of a given substructural unit to the
biological activity is a consistent factor. This, however,
is frequently not true where large and structurally di-
verse data sets for relatively unspecified biological ef-
fects are considered, since in such cases the biological
mechanism ofactionis likely tobe different fordifferent
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subsets of compounds. In addition, complex intramo-
lecularinteractions not accounted for by simple descrip-
tors may strongly influence the role of certain
substructures; in the extreme case they may be favor-
able for activity in one particular chemical environment
and unfavorable in another. In such a situation the di-
vision ofcompounds into classes with the sole criterion
ofmeasuredbiological activityvaluesisbasicallywrong,
since the classes so obtained do not constitute homo-
geneous andwell-defined entitiesbutconsistofdifferent
clusters withquite different characteristics. None ofthe
methods mentioned so far take this fact into account.
This has two serious consequences that one must be
well aware of: (1) a certain percentage ofpredictions is
bound to be wrong; (2) a classifier obtained from such
datamaybecomeverycomplexsinceitactuallypresents
amixture and acompromise ofseveralclassifiers needed
to separate different subsets ofcompounds in the active
class from the inactive compounds. Such classifiers ad-
mit no chemical interpretation, and even though they
may still be used as predictive tools in a purely algo-
rithmic sense (keeping in mind point 1), this situation
is far from being satisfactory for a medicinal chemist or
toxicologist.
Someoftheproblemsmentionedabove canbeavoided
by the third category oftopological methods, which we
have termed in this paper "topological pattern finders."
Let us first define what we understand by a "topological
pattern" in this context. We regard it as an ensemble
ofsubstructuralfeatures thatischaracteristic ofagroup
of compounds possessing a desired biological property
(e.g., high activity) but absent from compounds devoid
ofthis property. This ensemble, which may be called a
"topological pharmacophore," is always considered in
its entirety. This means, in particular, that no conclu-
sions about the importance of isolated features on bio-
logical activity is always seen to be dependent on the
other features present in the pharmacophore. In this
way the assumption that the contribution of a given
structural unit to the biological activity is a consistent
factor is no longer necessary; as discussed above this
assumption probably is not realistic for too complex
problem. Furthermore, it becomes possible to handle
data sets where the compounds do not act via a uniform
mechanism. If different mechanisms operate they will
be reflected by different topological pharmacophores.
It was for these reasons that we started to develop
topological techniques of the "pattern finding" type
(15,29-32,45). Two ofthem, the methods LOGANA and
LOCON (45), will be discussed in the next sections in
some detail together with a simple example of
application.
The LOGANA and LOCON Methods
In contrast to the index and classification methods,
where activity indices or weights are assigned to single
features, the basic structure of LOGANA and LOCON
is the stepwise and interactive construction of combi-
nations of such features using the logical operations
"and," "or," and "not." These combinations are evalu-
ated in such a way that they are typical of compounds
possessing the biological property of interest to the
highest extent (e.g., compounds with high or very high
activity, compounds devoid oftoxicity, etc.). They rep-
resent more or less complex structural patterns that
may be regarded as "topological pharmacophores" and
that can then aid in the design of new compounds. The
philosophy of both methods is to make use of the data
handling capacity of computers while maintaining an
optimal impact ofthe researcher's professional skill and
experience with no requirement for any special math-
ematicalknowledge. Thecomputerisused onlytodigest
large data sets and condense the information inherent
in them so that it becomes manageable. While this part
is fully formalized, the real decision-making and all the
conclusions to be drawn for further synthesis or testing
are completely left to the researcher. This implies that
neither assumptions regarding probabilities or data dis-
tribution nor mathematical models are necessary.
The program LOGANA starts from a classification of
the compounds of the training series according to a bi-
ological activity score which allows the analysis ofmore
or less crude data as from biological mass screening or
sampled from different sources. LOCON, on the other
hand, was designed to deal with continuous biological
activity data in order not to lose information in those
cases where the data are precise enough to allow for
comparisons on such a scale. Both methods are binary
descriptors as defined by Eq. (1), and they will be most
efficient fortemplate model derived features. Molecular
properties like, for instance, hydrophobicity can also be
included to a certain extent. This is done by selecting
region(s) (or threshholds) of the corresponding molec-
ular parameter (e.g., the log P or rr) and defining xi1 =
1 ifthejth compound falls into the ith region and xi1 =
0, if not.
The set of descriptors obtained according to Eq. (1)
or the above definition can be extended by the logical
operations "not" (negation, symbolized by a "-"sign)
and "or" (disjunction, symbolized by a "V" sign). In a
negation, the definitionpresented in Eq. (1) isreversed,
meaningthatthe absence oftheithfeature isconsidered
important and used as a new feature:
=1
xij =
i0,
if feature i is not present
in thejth compound (12)
if it is present
A disjunction combines several features which are re-
garded to be so similar that they can be exchanged
without noticeable effect on biological activity ("bio-
isosteric" features) into a new one. A disjunction oftwo
descriptors xi and Xk, for example, would read:
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if features i or k are present
in the kth compound
if neither feature i nor
feature k is present
LOGANA
Input into the program are the variables (topological
descriptors) and a classification with respect to the bi-
ological activity ofinterest (e.g., high activity) into two
classes (class 1: compounds with the desired biological
property; class 2: desired property not present) for all
compounds ofthe training series. Searched forare com-
binations offeatures (conjunctions, see below) that are
present in as large as possible groups of class 1 com-
pounds and absent or nearly absent in class 2 com-
pounds. It is this strategy that makes LOGANA basically
different from classification methods since these meth-
ods aim at a complete separation ofthe two classes. By
considering subgroups it becomes possible to account
for different mechanisms of action which may require
different pharmacophores. Another point is that a lim-
ited set ofnot too simple topological featuresbyits very
nature frequently implies the formation of subgroups.
Take, for example, the case that for a certain type of
activity a hydrogen donor is needed in some particular
region ofthe molecules while the chemical nature ofthis
donor is not important and that different donor types
appear in the compounds of the training series, each
described by a different variable. In this case different
topological patterns will result, each representing one
subgroup of compounds according to the donor type.
Onlyifthedifferentdonordescriptors arecombinedinto
one new variable by the logical "or" [disjunction, see
Eq. (13)] will the division into subgroups disappear but
thiswouldrequirethat acorresponding decisionis made
by the researcher.
The construction of more complex from the simple
features is based on the logical operation "and" (con-
junction, symbolized by a "A" sign). A conjunction of
two variables xi and xk is defined as
Xij AXik I
09,
if features i and kc
are present in the
jth compound
if not
Obviously, a conjunction represents a more complex
chemical entity than the single variables and will, as a
consequence, usually be present in a smaller set ofcom-
pounds. A set of compounds having the structural fea-
tures expressed by a conjunction in common will be
called an "object group." Those conjunctions can be re-
garded best which yield object groups containing high
numbers ofclass 1 compounds and the smallest possible
number of class 2 compounds. As a measure of this
(13) property a simple quality criterion T can be formulated
as
T= N1 + (n, - n2)
N,l + N2
with T normalized to
T 1
(15)
where N1 = number of compounds in class 1, N2 =
number of compounds in class 2, n1 = number of class
1 compounds in the object group, and n2 = number of
class 2 compounds in the object group.
The evaluation of the conjunction is preferred in a
stepwise procedure where one more variable is added
in each step using T as a selection criterion. In the first
step all variables (including negations) are arranged in
the order of descending T values and the best m vari-
ables (m adjustable) are selected as a starting set for
the next step. Conjunctions of each of the variables of
this starting set with all other variables one at a time
are then formed according to Eq. (14) and the best m
of these conjunctions are then printed out and trans-
ferred to the next step as a new starting set. Each
conjunction of this set is then again combined with all
variables (one at a time) by the logical operation "and,"
and the best m of the resulting conjunctions now com-
prising three variables are again printed out and trans-
ferredto the next step. The procedure is continued until
apreset number ofsteps has been performed. This step-
up procedure can be combined with feature elimination
steps at each level. Applied to the m best conjunction
comprising k variables afterthe kth forward step, back-
ward elimination will once eliminate each variable from
each conjunction and yield m "best" new conjunctions
now comprising k - 1 variables. The main purpose of
this option is to check for consistency.
Disjunctions [see Eq. (13)] will not be automatically
formed in order to limit the resulting conjunctions to a
manageable number. They can be introduced by a spe-
cial option at any stage of the procedure. Along with
each conjunction the following information appears in
the printout: T, n1, n2; the compounds of the object
group identified by the respective row numbers of the
input data matrix; and accompanyingvariables. Accom-
panying variables are those that can be added to a con-
junction withouteliminatingcompounds fromthe object
group. They must, of course, be considered when eval-
uatingtheresults sincetheycharacterize structural fea-
tures also present in all compounds ofthe object group.
The best conjunctions obtained after the analysis is
completed can directly be retranslated into topological
structures. In doing that and when interpreting the
results the whole picture including the development of
the conjunctions, the object groups described by them
and the accompanying variables must be viewed. It is
important to stress that the quality criterion T is not
to be used for decision-making by the researcher but is
XiJVX_J c
Xij Xkj -l
09,
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only an internal tool of the program. For a detailed
analysis it is usually advisable to investigate several
classifications in parallel as, for example, all active ver-
sus inactive, highly active versus weakly active and/or
inactive compounds, etc.
For linguistic simplicity it is tempting and practical
to label features appearing in the best conjunction
as"favorable" (or, in the case of negations, as "unfa-
vorable") for the biological activity considered. Strictly
speaking, this is not correct. All that can be concluded
isthat features represented inthe best conjunctions are
typical of the class 1 compounds, and that only in the
context ofthese conjunctions andinsofar, asthetraining
seriesisrepresentative ofthechemicalcompound space.
Because ofthe formation of subgroups, LOGANA is
not a procedure suitable for feature selection in order
to find a classifier. A special option of the program,
however, allows the evaluation of alternatives which
usually are good classifiers. Alternatively, several con-
junctions are combined by a logical "or" in such a way
that n, is maximized under the condition of an optimal
separation of class 1 and class 2 compounds. The alter-
native presents those conjunctions that optimally sup-
plementeachotherandprovidesinformation concerning
those objects of class 1 that can only be characterized
together with certain objects of class 2.
LOCON
LOCON searches for conjunctions expressing such
topological patterns that the corresponding object groups
(compounds having these patterns in common) show an
as high as possible mean value ofbiological activity. In
otherwords, topologicalpatterns aresearchedforwhich
are characteristic ofthe most active compounds. Input
into the program are the variables (topological descrip-
tors) and biological activity values for all compounds of
the training series. Biological activity is expressed here
on a continuous scale using quantities such as, for ex-
ample, ED,, Ix, or LDx, etc. Again, conjunctions are
derived in astepwise procedure by the logical operation
"and " [Eq. (14)]. The quality criterion used here to
characterize conjunctions (or variables) is defined as
D = (MS - MO) 1 + (NS)(W)
(NO)]-
much MS exceeds MO. As the T value in LOGANA, D
is only an internal tool of the program and not to be
used for interpretation and evaluation of the results.
In the first step of the analysis the variables are ar-
ranged in the order of descending D values, and the
best variables are selected as starting set for the next
step. Conjunctions ofthese best variables with all other
variables (including negations) one at a time are then
formed, and for each variable the m best (m adjustable)
conjunctions as judged by D are printed out together
with D, MS, the object group (compounds possessing
the structural features expressed by the conjunction),
the standard deviation, s, of biological activity in the
object group, outliers (compounds with a biological ac-
tivity differing more than ks from MS; k adjustable),
and accompanying variables (see above). From these
conjunctions the operator now selects those which he
considers the most promising or meaningful according
to all the available information and to his chemical in-
tuition by inspection. These are then used as starting
conjunctions and combined with all variables (one at a
time) in the next step. The best m ofthe resulting new
conjunctions now comprising three variables are again
printed out for each conjunction of the starting set. A
new starting set is then selected by inspection and ex-
tended by one variable in the next step. The procedure
is continued until the "quality" of the resulting con-
junction(s) as judged by D, MS, S and NS cannot be
further improved.
Concerning the interpretation of the results all that
has been said for LOGANA is also valid for LOCON.
Example: Carboxamides as Inhibitors of
Succinate Dehydrogenase
As a test case, LOGANA and LOCON (30) were ap-
plied to data on the inhibition ofsuccinate dehydrogen-
RX-(X -Z -(~ RY
X: A B C D E
o 0 N 0
Os IUN'
Os (16)
where MS = biological activity mean within the object
group described by the respective conjunction; MO =
overall mean (whole training series); NS = number of
compounds in the object group; NO = number of com-
pounds in the training series; W = adjustable weight
(¢ 0).
The higher the values of D become the more charac-
teristic is the corresponding conjunction ofthe high ac-
tivity compounds. With the weight W the influence of
the size of the object group on D can be adjusted. If
this is regarded to be ofsecondary importance W is set
equal to zero, and D will then solely depend on how
F G H I
11
0
L M N 0
CH3,
CH
CH
CH
CN
0
K
CH ,C3
11
CH
i-C4H9 n-C3H7
FIGURE 1. General structure of the carboxamides.
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Table 1. pI50 values for the inhibition of succinate dehydrogenase from Cryptococcus laurentii by carboxanilides of the general
structure depicted in Figure l.a
RY
3'-CH3
3'-CH3
2',3'-CH3
3'-CH3
2'-C6H5
3!-CH3
3'-OCH3
3'-Cl
2'-CH3
4'-Cl
2'-CH3
2',4'-CH3
2'-C2H5
2'-Cl
3'-OCH20-4'
2'-OCH3
3'-OCH3
2',3'-CH3
2',3'-Cl
2',3'-CH3
3-CH3
2'-CH3, 4'-OCH3
2'-CH3, 4'-Cl
4'-Br
3'-OCH3
2',3'-CH3
2'-CH3
2',3'-CH3
2'-CH3
2'-CH3
2',6'-CH3
2'-CH3
2',6'-C2H5
3'-CH3
3'-CH3
2'-CH3
2'-CH3
2'-CH3
3',4'-Cl
2'-OCH3
2'-CH3
3'-CH3
PI50
4.00
3.46
3.30
3.30
3.26
3.26
3.22
3.22
3.22
3.14
3.12
3.00
3.00
3.00
2.72
2.70
2.70
2.70
2.70
2.66
2.60
2.60
2.60
2.57
2.52
2.48
2.46
2.46
2.41
2.40
2.40
2.40
2.35
2.26
2.25
2.22
2.22
2.19
2.12
2.11
2.00
2.00
1.98
1.96
1.96
1.89
1.87
1.85
1.84
1.74
1.58
1.48
1.42
1.40
1.22
1.08
1.07
1.00
1.00
0.98
0.92
0.74
0.60
0.42
0.40
0.35
1.0
< 0.6
< 0.3
(continued)
No.
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
z x
CONH A
CONH B
CONH A
CONH C
CONH A
CONH A
CONH D
CONH D
CONH D
CONH B
CONH A
CONH A
CONH E
CONH C
CONH B
CONH A
CONH A
CONH A
CONH E
CONH B
CONH A
CONH E
CONH C
CONH C
CONH D
CONH F
CONH B
CONH F
CONH C
CONH A
CONH A
CONH C
CONH B
CONH C
CONH A
CONH E
CONH B
CONH G
CONH G
CONH G
CONH C
CONH B
CONH F
CONCH3 A
CONH D
CONH A
CONH C
CONH A
CONH F
CONH C
CONH C
CONH C
CONH G
CONH C
CONH F
CONH C
CONH C
CONH A
CONH H
CONH G
CONCH3 E
CONH C
CONH I
CONH F
CONH C
CONH K
CONH F
CONH C
CONH A
(RX)oXo
CH3
CH3, H
CH3
C2H5, H
CH3
CH3
CH3
CH3
CH3
CH3, H
CH3
CH3
C2H5, 2H
I, H
CH3, H
CH3
CH3
CH3
CH3, 2H
CH3, H
CH3
CH3, 2H
C2H5, H
C2H5, H
CH3
CH3
CH3, H
CH3
CH3, H
CH3
CH3
Br, H
CH3, H
CH3, H
CH3
CH3, 2H
CH3, H
CH3, H
CH3, H
CH3, H
CH3, H
CH3, H
CH3
CH3, H
CH3
CH3, H
C2H5, H
CH3, H
CH3
CH3, H
CH3, H
OH, H
CH3, H
OH, H
CH3
CH3, H
OH, H
CH3, H
CH3, H
CH3, H
CH3, 2H
CH3, H
CH3
H
C2H5, H
CH3
H
H, H
CH3, H
(RX)m,p
4H
CH3
4H
3H
4H
4H
NH2
NH2
NH2
CH3
4H
4H
4H
3H
CH3
4H
4H
4H
4H
CH3
4H
4H
3H
3H
CH3
2H
CH3
2H
3H
4H
4H
3H
CH3
3H
4H
4H
CH3
CH3
CH3
CH3
3H
H
2H
4H
CH3
4H
3H
4H
2H
3H
3H
3H
CH3
3H
2H
3H
3H
4H
4H
CH3
4H
3H
2H
CH3, H
3H
CH3, H
2H, CH3
4H
y
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
CPhlI
Phenyl
C6Hnl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
C6Hnl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
Phenyl
C4H9
Phenyl
Phenyl
Phenyl
H
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Table 1 (Continued)
No. Z X (RX)X,, (RX)m,p Y RY pIrO
70 COOH A CH3, H 4H < 0.3
71 CONH E C6H5, 2H 4H Phenyl < 0.3
72 CONH C H, H 3H Phenyl < 0.3
73 CONH C F, H 3H Phenyl < 0.3
74 CONH C H, H CH3, 2H Phenyl < 0.3
75 COCH2 B CH3, H H Phenyl < 0.3
76 CONH I H CH3, H Phenyl < 0.3
77 CONH F CH3 2H CH3 < 0.3
78 CONH F CH3 2H C4Hq < 0.3
79 CONH F H CH3, H Phenyl < 0.3
80 CONH F H CH3, H Phenyl 2',3'-CH3 < 0.3
81 CONH F H CH3, H C6H11 <0.3
82 CONH 0 Phenyl < 0.3
83 CSNH C CH3, H 3H Phenyl < 0.1
84 SO2NH C CH3, H 3H Phenyl < 0.1
85 CSNH B CH3, H H Phenyl 0.0
86 CONH E H, 2H 4H Phenyl 0.0
87 CONH M Phenyl 0.0
88 CONH L Phenyl 0.0
89 CONH N Phenyl 0.0
aData from White and Thorn (46).
ase by a series of antifungal carboxamides (46) of the
general structure presented in Figure 1. This example
was selectedbecausethetrainingseries showssufficient
structural diversity and the data allow the application
of both, LOGANA and LOCON (the former after di-
vision of the compounds into classes; see below).
All compounds and their activities are summarized in
Table 1. The features used in this case are selected so
that not only the type of substructures but also the
region in the molecules where they are situated can be
coded for. Table 2 represents the features used in LO-
GANA and Table 3 some additional features applied in
LOCON only. These additional features were defined
after the results of LOGANA were known with the
intention to increase the sharpness of the LOCON an-
alysis. We have always found it useful to apply LO-
GANA even to continuous data (after introducing a
classification) prior to a LOCON analysis since LO-
GANA works faster and its results may be used to
improve or complete the feature space for the more
powerful LOCON procedure. Finally, Table 4 contains
the code of all compounds in terms of the binary de-
scriptors defined according to Eq. (1).
LOGANAResults. LOGANAwasappliedtothefol-
lowing classifications:
Problem A: active versus inactive compounds
Class 1(A)
Class 2(A)
0.60
-
Problem B: highly versus
PI50 -,- 4.00 Nl(A) = 64
PI50 < 0.60 N2(A) = 25
weakly active compounds
Class 1(C)
Class 2(C)
3.00 S PI50 P 4.00
P'50 < 0.60
Nl(c)
N2(c)
= 14
= 25
The development ofthe best conjunction obtained for
problem A [conjunction (I)] is presented in Table 5*.
This conjunction is present in almost all class 1(A) com-
pounds and does not occurin any ofthe inactive analogs
[class 2(A) compounds]. It can directly be translated
into the structure shown in Figure 2. This structure
may be regarded to present basic structural require-
ments for activity which include an intact amide group
(variable Z1), a substituent different from H, F or phenyl
in the ortho position ofX (variables RX7, RX8, RX9),
a C=C group adjacent to the carbon atom ofthe amide
moiety which is part of a ring, and a ring adjacent to
the amide nitrogen. Another conjunction ofinterest for
a subset of class 1(A) compounds is:
X16A - Y6A (Z1VZ2) ARX1
with nl(A) = 30, n2(A, = 0
(II)
The compounds ofthis subset have an oxygen adjacent
to the C =C group in Figure 1 (feature X16) and methyl
in (RX),,,1I. It cannot be said whether this more spec-
ified patternprovides higheractivitythanthatinFigure
2 but it is certainly ofinterest to know that it is present
in about 50% of the class 1(A) compounds while also
absent from all inactive analogs.
Some additional information about what features may
be important for gradation ofactivity within the active
compounds was expected from problem B. The best
conjunction obtained for that problem is
2.00
- PI-oS 4.00
0.60 PI50o 1.70
N1(B) = 40
N2(B)= 19
Problem C: very active versus inactive compounds
RY16 A
- X6A - RY14 A
- RY15 A - X7 A RX1
with nl(B) = 21, n2(B) = 2
Accompanying variables: Zi, Y1, X8, X9, RX11
Class 1(B)
Class 2(B)
(III)
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Definition
-CONH-
-CONCH3-
-COOH
-COCH2-
-CSNH-
-SO2NH-
X = structures A- 0
-c = c-c = 0
-0-C = C-C = 0
-S-C-C = 0
in Z
in Z
in Z
in Z
in Z
in Z
in X
in X
in X
Tble 3. Additional features derived for the application of
LOCON: xi = 1 if feature i is present.
X18 X10 V Xll V X12 V X13 V X14
X19 X2A RX11
X20 X4 A RX10
X21 X4ARX11
X22 X6/ARX11
X23 X7/ARX11
X24 X9ARX11
RX12 RX7 V RX9
RX13 RX3 V RX4 V RX5 V RX9
RY17 RY2 V RY3 V RY8 V RY11
RY18 RY14 V RY15
RY19 RY6 V RY7 V RY12 V RY13
RX1
RX2
RX3
RX4
RX5
RX6
RX7
RX8
RX9
RX10
RXl1
Y1
Y2
Y3
Y4
Y5
Y6
RY1
RY2
RY3
RY4
RY5
RY6
RY7
RY8
RY9
RY10
RY11
RY12
RY13
RY14
RY15
RY16
aSymbols as in Figure 1.
-CH3
-C2H5
-I
-Br
-Ci
-OH
-H
-phenyl
-F
-NH2
-CH3
-phenyl
-cyclohexyl
-butyl
-H
-methyl
no ring
3'-CH3
2'-CH3
2'-C6H5
3'3'-OCH3
3'-Ci
4'-Cl
4'-CH3
2'-C2H5
2'-C1
3'-OCH20-4'
2'-OCH3
4'-OCH3
4'-Br
6'-CH3
6'-C2H5
R. with ff > 0
in (RX),,
in (RX)0
in (RX),,
in (RX)0
in (RX),,
in (RX),
in (RX),
in (RX)o
in (RX)0
in (RX)o
in (RX)o,m,p
in Y
in Y
in Y
in Y
in Y
in Y
The structure obtained from this conjunction (Fig. 3) is
present in about 50% ofthe very active and in only two
out of the 19 weakly active compounds. The additional
information as compared to conjunction (I) and (II) is
that, for high activity, the ring attached to the nitrogen
of the amide group should be phenyl (or, maybe, in a
more general sense simply aromatic) and that hydro-
phobic substituents at this ring are favorable as long as
an o, o'-disubstitution is avoided. Several other con-
junctions also containingthese but in addition some spe-
cial X-ring features describe the rest of the class 1(B)
compounds without, however, providing much useful
additional information. For this reason they will not be
discussed.
Problem C, finally, yields the following results:
RY16 A X6 (IV)
with nl(c) = 10, n2(C) = 0
Accompanying variables: Z1, X5, -X9, X10,
-
X1i, =- X12,
- X13, X14,
- X15, RX3,
- RX7,
RX8, RX9, Y1
Conjunction IV leads to the structure presented in Fig-
ure 4 which shows all the basic features ofconjunctions
(I) and (II) but also provides some of the additional
information obtained from conjunction (III) (see Fig. 3).
The lesson to be learned from this is that compounds of
medium activity may well be eliminated from a LO-
GANA analysis. As in the present and other examples
[(31) andunpublishedwork]theresultisusuallysharper
and by no means less representative as for the whole
data set [conjunctions (I) and (II)]. Especially for very
large training series a lot of work can be saved in this
way.
LOCONResults. Two relatively small conjunctions
comprising three variables already produce object groups
C - RX #H, phenyl, F
ring 11
C-C- N-( ng
O H
FIGURE 2. Structural pattern resulting from conjunction I.
C-CH3 RY (1Y>O), not o, o' disubstituted
ring C-C-N -/
O H
FIGURE 3. Structural pattern resulting from conjunction III.
,CH3 or C2H RY (T1 >0)
II
H
FIGURE 4. structural pattern resulting from conjunction IV.
Table 2. Definition of descriptors xi used in LOGANA: xi = 1
if feature i is present.a
Feature
zi
Z2
Z3
Z4
Z5
Z6
Xl- X14
X15
X16
X17
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Table 4. Features having the value ofx, = 1 for all compounds.
Compound Additional features used
No. Features used in both LOGANA and LOCON in LOCON only
1 Z1, X1, X15, X16, X17, RX1, Y1, RY1, RY16
2 Zi, X2, X15, X16, RX1, RX11, Yl, RY1, RY16
3 Zl, Xl, X15, X16, X17, RX1, RY1, RY2
4 Z1, X3, X15, RX2, Y1, RY1, RY16
5 Zi, Xi, X15, X16, X17, RX1, Y1
6 Zi, X1, X15, X16, X17, RX1, Y1, RY3, RY16
7 Zi, X4, X15, X17, RX1, RX10, Y1
8 Z1, X4, X15, X17, RX1, RX10, Y1, RY1, RY16
9 Zi, X4, X15, X17, RX1, RX10, Y1, RY4, RY16
10 Zi, X2, X15, X16, RX1, RX11, Yl, RY5, RY16
11 Zi, X1, X15, X16, X17, RX1, Y1, RY2, RY16
12 Zi, X1, X15, X16, X17, RX1, Y1, RY6, RY16
13 Zi, X5, X15, X16, RX2, Y1
14 Z1, X3, X15, RX3, Y1
15 Zl, X2, X15, X16, RX1, RX11, Y1, RY2, RY16
16 Zi, Xl, X15, X16, X17, RX1, Y1, RY2, RY7, RY16
17 Z1, X1, X15, X16, X17, RX1, Y1, RY8, RY16
18 Z1, Xi, X15, X16, X17, RX1, Y1, RY9, RY16
19 Zi, X5, X15, X16, RX1, Y1, RY10, RY16
20 Z1, X2, X15, X16, RX1, RX11, Y1
21 Zi, Xl, X15, X16, X17, RX1, Y1, RY11
22 Zl, X5, X15, X16, RX1, Y1, RY4, RY16
23 Z1, X3, X15, RX2, Yl, RY1, RY2, RY16
24 Zl, X3, X15, RX2, Y1
25 Z1, X4, X15, RX1, RX11, Y1
26 Z1, X6, X15, X17, RX1, Y1
27 Z1, X2, X15, X16, RX1, RX11, Y1, RY5, RY9
28 Zi, X6, X15, X17, RX1, Y1, RY1, RY2, RY16
29 Zl, X3, X15, RX1, Yl, RY1, RY16
30 Zi, X1, X15, X16, X17, RX1, Y1, RY2, RY12, RY16
31 Zl, Xl, X15, X16, X17, RX1, Y1, RY2, RY6, RY16
32 Z1, X3, X15, RX4, Y1
33 Z1, X2, X15, X16, RX1, RX11, Y1, RY13, RY16
34 Zl, X3, X15, RX1, Y1, RY4, RY16
35 Z1, Xl, X15, X15, X17, RX1, Y2
36 Z1, X5, X15, X16, RX1, Y1
37 Zl, X2, X15, X16, RX1, RX11, Y2
38 Zi, X7, X15, RX1, RX11, Y1, RY1, RY2, RY16
39 Zi, X7, X15, RX1, Xll, Y1, RY2, RY16
40 Zi, X7, X15, RX1, RX11, Y1
41 Zi, X3, X15, RX1, Y1, RY1, RY2, RY16
42 Zi, X2, X15, X16, RX1, Y1
43 Zi, X6, X15, X17, RX1, Y1, RY2, RY16
44 Z2, X1, X15, X16, X17, RX1, Y1
45 Z1, X4, X15, X17, RX1, RX11, Y1, RY2, RY16
46 Zi, Xl, X15, X16, X17, RX1, Y1, RY2, RY14, RY16
47 Zl, X3, X15, RX2, Y1, RY2, RY16
48 Z1, X1, X15, X16, X17, RX1, Y1, RY3, RY15, RY16
49 Z1, X6, X15, RX1, Y1, RY1, RY16
50 Zl, X3, X15, RX1, Y1
51 Zi, X1, X15, RX5, Y1
52 Zl, X3, X15, RX6, Y1, RY1, RY16
53 Zl, X7, X15, RX1, RX11, Yl, RY2, RY16
54 Z1, X3, X15, RX6, Y1, RY2, RY16
55 Zi, X6, X15, X17, RX1, Y2
56 Z1, X3, X15, RX1, Y1, RY2, RY16
57 Z1, X3, X15, RX6, Y1
58 Z1, X1, X15, X16, X17, RX1, Y1, RY5, RY6, RY16
59 Z1, X8, X15, X16, X17, RX1, Y1
60 Zi, X7, X15, RX1, RX11, Y2
61 Z2, X5, X15, X16, RX1, Y1
62 Zi, X3, X15, RX1, Y1, RY11
63 Zi, X9, X15, RX1, Yl
64 Zi, Xt, X15, RX7, RX11, Yl, RY2, RY16
65 Zi, X3, X15, RX2, Y3, Y6
66 Zi, X10, X15, RX1, Yi
67 Zi, X6, X15, RX7, RX11, Yl, RY1, RY16
RY20
X19, RY17, Ry2O
RY20
RY20
RY17
X20
RY20
X20, RY20
X19, RY20
RY17
RY19
RX13
X19, RY17
RY17, RY19
RY17
RY17
RY19, RY20
X19
RY17
RY20
RY17, RY20
X21
X19, RY17, RY20
RY17, RY20
RY20
RY17, RY19
RY17, RY19
RX13
X19, RY19
RY20
X19
X24, RY17, RY20
RY17
RY17, RY20
RY17
X21, RY17
RY17, RY18
RY17
RY17, RY18
RY20
RX13
RY20
X24, RY17
RY17
RY17
RY19, RY20
X23
RY17
X22, RX12, RY17
X18
RX12, RY20
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Table 4. (Continued)
Compound Additional features used
No. Features used in both LOGANA and LOCON in LOCON only
68 Zl, X3, X15, RX7, RX11, Y1 RX12
69 Zi, Xl, X15, X16, X17, RX1, Y4, Y6
70 Z3, Xl, X15, X16, X17, RX1, Y6
71 Zl, X5, X15, X16, RX2, RX8, Y1
72 Z11/8, X3, RX7, Y1 RX12
73 Zl, X3, RX9, Y1 RX12, RX13
74 Zl, X3, RX7, RX11, Yl RX12
75 Z4, X2, X15, X16, RX1, Y1
76 Zl, X9, X15, RX7, RX11, Y1
77 Zi, X6, X15, X17, RX1, Y5, Y6
78 Zi, X6, X15, X17, RX1, Y3, Y6
79 Zi, X6, X15, X17, RX7, RX11, Y1 RX12
80 Zi, X6, X15, X17, RX7, RX11, Yl, RY1, RY2, RY16 RX12, RY17, RY20
81 Zl, X6, X15, X17, RX7, RX11, Y2 RX12
82 Zi, X14, Y1 X18
83 Z5, X3, X15, RX1, Y1
84 Z6, X3, X15, RX1, Y1
85 Z5, X2, X15, X16, RX1, Yl
86 Zi, X5, X15, X16, RX7, Yl
87 Zi, X13, Yl X18
88 Z1, X2, X15, Yl X18
89 Zl, X12, Yl X18
Table 5. Development of the best LOGANA conjunction (no. I)
obtained for problem A.
Conjunction n1A 82A
X15 64 19
X15 A - RX7 63 12
X15A
- RX7A - Y6 63 7
X15A - RX7A - Y6AZl 61 3
X15 A - RX7 A - Y6 A Zl A- (XlO V X11) 61 1
X15A - RX7A - Y6AZl A - (X1OVX11)
A - RX85 61 0
aAccompanyg variables: X12, X13, X14, RX9.
with means MS well above the global mean of MO =
1.67:
Z1 A RX1 A Y1 (V)
with MS = 2.33, NS = 47, s = 0.793
Accompanying variables: X15, - Xll, - X12, - X13,
- X14
X15 A RY16 A (RX7 V RX9) (VI)
MS = 2.46, NS = 37, s = 0.675
Accompanying variables: Z1, - Y1, - X10, - Xll, -
X12, - X13, - X14,
- X24
Both conjunctions represent large parts of the active
compounds and therefore tell the same story as the
LOGANAconjunctionscharacterizingbasicfeatures for
activity. The development of an already more specific
conjunction (VII) is shown in Table 6. Translating back
this conjunction to structural terms leads to Figure 5.
As was to be expected this structure contains all fea-
tures already known to be important for very high ac-
tivity (see Fig. 3) but yields the additional information
Table 6. Development of a conjunction (no. VIII) describing
a group of very active compounds.
Conjunction MS NS s
X16 V X20 2.21 40 1.099
(X16 V X20) A RY16 2.57 22 0.660
(X16 V X20) A RY16 A - RY18 2.67 20 0.608
(X16 V X20) A RY16 A
-
RY18 A
- RY19a 3.04 14 0.3666
aAccompanying variables: Zl, Yl, -RX8, -X3, -X21,
- X8, -X1i, -X12, -X13, -X14, -X22, -X23,
- X24.
thatthephenylringadjacdent tothe nitrogenis notpara-
substituted and thatthe structure -N = C -(NH2) -S -
(variableX20) also istypicalofhigh activity compounds.
As in conjunction (IV), several X-ring structures are
indicated as not being representative for high activity.
Conjunction (VII) cannot be interpreted to mean that
para-substituents, for example, are always unfavorable
for high activity (see compound 12) or that phenyl is an
"unfavorable" moiety to be placed in X (see compounds
4 and 14). What it in face means is that, within the
training series, a set ofcompounds exists that have the
features presented by this conjunction in common and
that are all highly active so that it can be regarded a
r 11 ~~~RY(ITY>0)
riC- _ -not o, o-disubstituted
11 / -not p-substituted
or: 0 H
N-
H2N S
FIGURE 5. Structural pattern resulting from conjunction VII.
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reasonable approach to start from these features when
synthesizing new compounds.
Ifthe variable RY1 is added to conjunction (VII) one
obtains:
(X16 VX20) A RY16 A RY18 A RY19 A RY1
(VIII)
MS = 3.42, NS = 5, s = 0.343
This conjunction yields an object group with a very high
activity mean but is less representative because of the
small number ofcompounds (onlyfive) involved. It may,
nevertheless, be taken as an indication that methyl sub-
stitution inthe metaposition ofYmaybeanothertypical
feature ofthe very active compounds. This can be sup-
ported by the following simple conjunction which also
contains RY1 as variable and shows MS well above the
overall mean:
Y1 A RX12 A RY1 (XII)
with MS = 2.64, NS = 11, s = 0.767
If one tests other RY substituents in a similar way it
can be seen, for example, that the 2-CH3 group is much
less typical ofhigh activity. Thus, in synthesizing com-
pounds supposed to show very high activity it would be
a reasonable concept to place a methyl (or a similar)
group in the meta position of Y but not in the ortho or
para position.
Summarizing Conclusions. Both, LOGANA and
LOCON, yield consistent results which allow one to
formulate somegeneralrulesforhighactivity asfollows:
* Presence of the intact amide group
* Ring in position X (see Figure 1) that has a C =C
double bond adjacent to the C atom of the amide
moiety
* "Favorable" rings are those which have an oxygen
in the upper meta position ofX (as, e.g., in ring A)
with respect to the amide group and, possibly, sul-
fur in the ortho position. A feature to be avoided in
X is ring H.
* RX in ortho position of X must not be H, F, or
phenyl. Atypicalsubstituent inthispositionis CH3.
This may be interpreted to mean that substituents
of medium size are favorable for high activity
* Phenyl (or, possibly, other aromatic units) in Y
* RY should be hydrophobic andbe placed inthe meta
position
These conclusions well agree with the results ob-
tained from an earlier topological analysis based on in-
formation theory (29) and with results from
nonelementary discriminant analysis (47) as well as with
empirical rules known for the type of antifungal com-
pounds considered. Since in discriminant analysis phys-
icochemical parameters were used (together with
indicator variables), a comparison ofthe conclusions from
discriminant analysis with the present results may be
of interest. The four most important variables appear-
ing in the discriminant function separating the active
compounds into three classes are:f(X), the hydropho-
bicity of X; r,,,2(X), where uc,,(X) is the electronic sub-
stituent constant characterizingtheuppermetaposition
(with respect to the amide moiety) in ring X; MR(RX)O,
molar refractivity of RX substituents in the ortho po-
sition; and i.,,(RY), the hydrophobicity of RY substi-
tuents in the meta position. The directionality of these
variables is such that increasing values increase the
probability that a compound will belong to the most
active class.
The first variable indicates that the hydrophobicity
of X plays some role, while the second shows that the
type ofatom in the meta position ofX is important. The
conclusion is the same as from LOGANA and LOCON,
namely, that an oxygen in this position should be a good
choice. The MR(RX)O variable indicates the importance
of the substituent in ortho position of X and ofits size,
which also clearly came out as one ofthemostimportant
features from LOGANA and LOCON. In accordance
with rule 6 (see above), the ar,(RY) variable, finally
indicates that hydrophobic substituents in the meta po-
sition of the phenyl ring in Y are obviously activity-
enhancing. Ifthe separation ofactive frominactive com-
pounds is investigated by discriminant analysis, the re-
sult is identical with that represented by conjunction
(1).
It is quite satisfactory that two completely different
types of methods using different types of descriptors
lead to consistent results. The advantage of LOGANA
and LOCON when compared with discriminant analysis
in the present case is that the results are obtained in a
very straightforward manner directly leading to chem-
ical structures while the complete discriminant function
is so complex that it does not admit ofa chemical inter-
pretation. Though the patterns found by LOGANA and
LOCON provide a good systematization of the com-
pounds in structural terms allowing one to understand
why active compounds are active, they would probably
not lead to novel structures ofoutstanding activity. This,
however, is not a problem with the method but rather
connected with the fact that the training series, though
structurally diverse, is still too limited for elucidating
structuralinformation whichcouldberegarded as atrue
surprise. According to the above rules acompound with
X = ring A, RXO = CH3, Z = CONH, Y = phenyl
and RY = m-CH3 should be a very good candidate for
high activity. This compound, however, has already been
made and is the most active in the training series (No.
1 in Table 1).
Concluding Remarks
The results of this analysis and further examples
(31,32, and unpublished work) show that LOGANA and
LOCON are capable of handling quite diverse struc-
turesandprovide aclearandconsistent picture ofstruc-
tural patterns typical ofactivity in general and ofhigh
activity in particular. Although the data considered are
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not very extensive, the structural variation in the train-
ing series is already too extensive to allow the appli-
cation of simple linear QSAR models as, for example,
Hansch orFree-Wilson analysis. None ofthese methods
gives satisfactory results in the present case so that a
topological analysis is the only choice. LOGANA and
LOCON have the following advantages:
*No assumptions about additivity of effects or linear
models are necessary.
*The contribution ofa given structural feature to the
biological activity need not be a consistent factor.
*A uniform mechanism ofaction for all compounds of
the training series is not required. Ifdifferent mech-
anisms are operating they will be reflected by dif-
ferent pharmacophores provided, of course, that a
representative number ofcompounds exists for each
mechanism.
*There is no dependence on data distribution or sta-
tistical formalisms.
*Full use is made of the intuition and experience of
the researcher.
*The results are directly obtained in terms ofa struc-
tural pattern.
*Physicochemical molecular parameters are usually
not needed. Only when the variation ofsubstituents
becomes an important property are substituent con-
stants required to parametrize substituents via bi-
nary descriptors (31,32). Even then, however,
approximate values are sufficient.
*The methods can be applied to extremely diverse
data sets where linear free energy formalisms are
bound to fail. Inactive compounds can be included in
the calculation.
*For LOGANA, biological activity need not be avail-
able on a continuous scale. A simple classification is
sufficient so that it is possible to use data from mass
screening or sampled over a long period of time or
even from different sources.
Most specific for LOGANA and LOCON are the sec-
ond through sixth points above, while the others are
shared by the majority ofthe othertypological methods
mentioned in a previous section. It should be mentioned
in this context that the STRAC procedure also uses the
interactive construction of conjunctions by logical op-
erations with decision-making by the operator. The ob-
jective, however, is different from LOGANA in that
not a topological pattern but the evaluation of discrim-
inating features with the final purpose of classifying
compounds via probability-derived criteria is aimed at.
Other differences are that STRAC cannot handle very
large and diverse data sets and that it is directly at lead
optimization while LOGANA and LOCON are more of
the lead generation type.
Which ofthe topological procedures available and what
kind of features are to be applied in a particular case
depend on the data and the objective of the analysis.
LOGANA and LOCON are the methods ofchoice when
notonlythetypeofsubstructuresbutalsothemolecular
region where they occur can be (at least loosely) coded
for and when the primary purpose of the analysis is to
evaluate basic principles of a given type of biological
activity in terms ofchemical topology. Once these prin-
ciples are known the action ofcompounds may be better
understood and systematized, and it becomes possible
to design new structures possessing the desired type of
biological activity. This also includes the possibility to
design compounds which are not likely to possess an
undesired side effect (e.g., a certain type of chemical
hazard) when the corresponding topological pattern has
been evaluated. The design space can be extended by
introducing the concept of bioisosterism in a similar
manner as, for example, in Magee's RANGE procedure
(48).
When simple classification or preselection of already
existing compounds and not so much interpretation and
design are in the foregroundthe "index" orclassification
methods outlined above are tobe applied. Such methods
have also been applied in the field of chemical hazards
such as toxic effects (49,50) carcinogenicity (20,49-52),
and mutagenicity (43,44,49) not without success, al-
though the results thus far obtained more or less suffer
from the deficiencies discussed earlier (e.g., extremely
complex classifier). Considering the number of chemi-
cals already in circulation and those to be expected from
further syntheses, such analyses are to be regarded as
indispensable tools to set priorities for biological test-
ing. It is important to be well aware oftheir limitations
which, in particular, means that predicted data should
never be taken for granted and must not be allowed to
replace experimental measurements (53).
When applying topological methods one must, of
course, keep in mind several restrictions and possible
pitfalls partly already discussed. As in any QSAR method
the properties of the training series are crucial for the
validity of the results. Structural variations not ade-
quately represented in the training series can also not
adequately be reflected by the results. For LOGANA
and LOCON, forexample, thishasthe consequence that
the patterns evaluated cannot be regarded as a general
or final solution. All that can be said is that they are
typical of the highly active analogs in that part of the
chemicalcompound spacethatiscoveredbythetraining
series and that there is a high probability of finding
otherhighlyactive compounds ifthesepatterns areused
as a design criterion.
A very serious limitation ofall topological approaches
results from the fact that the actual events of drug-
receptor interactions are three-dimensional and dy-
namic, while these methods are static and operate in
only two dimensions. Topological approaches will,
therefore, yield validresultsonly tothe extentthattwo-
dimensional chemical structures reflect the much more
complicated processes operating when drugs interact
with biological targets. This implies that in a number
of cases such methods are bound to fail because the
topological descriptions of structures is inadequate; even
if geometrical descriptors are added (8), which can, in
principle, Be done in allmethods, this would stillbe true
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because of the static kind of approach. Molecular mod-
eling techniques are then the most promising way to go
but even in connection with such methods topological
analyses can be very valuable since their results may
provide hypotheses which can be used as an input when
applying the more sophisticated techniques.
REFERENCES
1. Purcell, W. P., Bass, G. E., and Clayton, J. M. Strategy in Drug
Design, A Molecular Guide to Biological Activity. Wiley-Inter-
science, New York, 1973.
2. Tichy, M., Ed. Quantitative Structure-Activity Analysis. Aka-
demiai Kiado, Budapest, 1976.
3. Buisman, J. A. K., Ed. Biological Activity and Chemical Struc-
ture, Pharmacochemistry Library, Vol. 2. Elsevier, Amsterdam,
1977.
4. Martin, Y. C. Drug Design Methods: A Critical Introduction.
Marcel Dekker, New York, 1978.
5. Franke, R., and Oehme, P., Eds. Quantitative Structure-Activity
Analysis, Akademie-Verlag, Berlin, 1978.
6. Golender, V. E., and Rozenblit, A. B. Computer Assisted Meth-
ods of Drug Design. Zinatne, Riga, 1978 (in Russian).
7. Seydel, J. K., and Schaper, K. J. Chemische Struktur und biol-
ogische Aktivitaet von Wirkstoffen. Verlag Chemie, Weinheim,
1979.
8. Stuper, A. J., Bruegger, W. E., and Jurs, P. C. Computer As-
sisted Studies of Chemical Structure and Biological Function.
Wiley, New York, 1979.
9. Olson, E. C., and Christoffersen, R. E., Eds. Computer-Assisted
Drug Design. ACS Symposium Series 112, American Chemical
Society, Washington, DC, 1979.
10. Knoll, J., and Darvas, F., Eds. Chemical Structure-Biological
Activity Relationships. Akademiai Kiado, Budapest, 1980.
11. Franke, R. Optimierungsniethoden in der Wirkstofforschung.
Akademie-Verlag, Berlinr-1980.
12. Dearden, J. C., Ed. Quantitative Approaches to Drug Design.
Pharmacochemistry Library, Vol. 6. Elsevier, Amsterdam, 1983.
13. Topliss, J. G., Ed. Quantitative Structure-Activity Relationships
of Drugs. Academic Press, New York, 1983.
14. Kuchar, M., Ed. Quantitative Structure-Activity Relationships
in Design ofBioactive Compounds. J. A. Prous, S. A., Barcelona,
in press.
15. Franke, R. Theoretical Drug Design Methods. Pharmacochem-
istry Library, Vol. 7. Elsevier, Amsterdam, 1984.
16. Leffler, J. E., and Grunewald, E. Rates and Equilibria ofOrganic
Reactions. Wiley, New York, 1963.
17. Adamson, G. W., and Bawden, D. A. Substructural analysis
methods for structure-activity correlation of heterocyclic com-
pounds using Wiswesser line notation. J. Chem. Inf. Comput.
Sci. 17: 164-171 (1977).
18. Bawden, D. Computerized chemical structure-handling tech-
niques in structure-activity studies and molecular property pre-
diction. J. Chem. Inf. Comput. Sci. 23: 14-22 (1983).
19. Smith, E. G., and Baker, P. A. The Wiswesser Line-Formula
Chemical Notation, 3rd ed. Chemical Information Management
Inc., Cherry Hill, NJ, 1975.
20. Jurs, P. C., Chou, J. T., and Yuan, M. Computer-assisted struc-
ture-activity studies of chemical carcinogens. A heterogeneous
data set. J. Med. Chem. 22: 476-483 (1979).
21. Kirschner, G. L., and Kowalski, B. R. The application ofpattern
recognition to drug design. In: Drug Design, Vol. VIII (E. J.
Ariens, Ed.), Academic Press, New York, 1979, pp. 73-131.
22. Golender, V. E., and Rozenblit, A. B. Logico-structural approach
to computer-assisted drug design. In: Drug Design, Vol. IX (E.
J. Ariens, Ed.), Academic Press, New York, 1980, pp. 299-337.
23. Avidon, V. V., Pomerantsev, I. A., Golender, V. E., and Roz-
enblit, A. B. Structure-activity oriented languages for chemical
structure representation. J. Chem. Inf. Comput. Sci. 22: 207-214
(1982).
24. Rozenblit, A. B. Computer-assisted drug design. Strategy and
algorithms. In: Strategy in Drug Design (J. A. Keverling Buis-
man, Ed.), Elsevier, Amsterdam, 1982, pp. 287-307.
25. Cammarata, A., and Menon, G. K. Pattern recognition classifi-
cation oftherapeutic agents accordingtopharmacophore. J. Med.
Chem. 19: 739-748 (1976).
26. Menon, G. K., and Cammarata, A. Pattern recognition. II. In-
vestigation of structure-activity relationships. J. Pharm Sci. 66:
304-314 (1977).
27. Henry, D. R., and Block, J. H. Classification of drugs by dis-
criminantanalysis usingfragmentmolecular connectivity. J. Med.
Chem. 22: 465-472 (1979).
28. Henry, D. R., and Block, J. H. Pattern recognition of steroids
using fragment molecular connectivity. Eur. J. Med. Chem. 15:
133-138 (1980).
29. Huebel, S., Roesner, T., and Franke, R. The evaluation of to-
pological pharmacophores by heuristic approach. Pharmazie 35:
424-433 (1980).
30. Franke, R., Streich, W. J., and Huebel, S. Topological phar-
macophores from continuous biological activity data. Studia Bio-
phys. 97: 11-20 (1983).
31. Franke, R., and Streich, W. J. Topological pharmacophores: new
methods and their application to a set ofantimalarials. 2. Results
from LOGANA. Quant. Struct. Act. Relat., in press.
32. Franke, R., and Streich, W. J. Topological pharmacophores: new
methods and their application to a set ofantimalarials. 3. Results
from LOCON. Quant. Struct. Act. Relat., in press.
33. Mercer, C., and Dubois, J. E. Comparison of molecular connec-
tivity and DARC/PELCO methods: performance in antimicrobial
halogenated phenol QSARs. Eur. J. Med. Chem. 14: 415-423
(1979).
34. Balaban, A. T., Chiriac, A., Motoc, I., and Simon, Z. Steric Fit
in Quantitative Structure-Activity Relations. Springer-Verlag,
Berlin, 1980.
35. Kier, L. B., and Hall, L. H. Molecular Connectivity in Chemistry
and Drug Research. Academic Press, New York, 1976.
36. Adamson, G. W., and Bawden, D. An empirical method ofstruc-
ture-activity correlation for polysubstituted cyclic compounds us-
ingWiswesser line notation. J. Chem. Inf. Comput. Sci. 16: 161-
165 (1976).
37. Adamson, G. W., and Bawden, D. Substructural analysis tech-
niques for empirical struct"ure-property correlation. Application
to stereochemically related molecular properties. J. Chem. Inf.
Comput. Sci. 20: 97-100 (1980).
38. Cramer, R. D., and Redl, G., and Berkoff, C. E. Substructural
apalysis. A novel approach to the problem ofdrugdesign. J. Med.
Cliem. 17: 533-535 (1974).
39. Hodes, L., Hazard, G. F., Geran, R. I., Richman, S. A statistical-
heuristic method for automatic selection of drugs for screening.
J. Med. Chem. 20: 469-475 (1977).
40. Hodes, L. Computer-aided selection ofnovel antitumor drugs for
animal screening. In: Computer-Assisted Drug Design (E. C.
Olsen and R. E. Christopherson, Eds.), ACS Symp. Ser. 112,
American Chemical Society, Washington, DC, 1979, pp. 583-602.
41. Hodes, L. Computer-aided selection ofcompounds for antitumor
screening: validation of a statistical-heuristic method. J. Chem.
Inf. Comput. Sci. 21: 128-132 (1981).
42. Hodes, L. Selection ofmolecular fragment features for structure-
activity studies in antitumor screening. J. Chem. Inf. Comput.
Sci. 21: 132-136 (1981).
43. Tinker, J. F. Relating Mutagenicity to Chemical Structure. J.
Chem. Inf. Comput. Sci. 21: 3-7 (1981).
44. Tinker, J. F. A computerized structure-activity correlation pro-
gramforrelatingbacterial mutagenesis activity to chemical struc-
ture. J. Comput. Chem. 2: 231-243 (1981).
45. Streich, W. J., and Franke, R. Topological pharmacophores: new
methods and their application. 1. The methods LOGANA and
LOCON. Quant. Struct. Act. Relat. 4: 13-18 (1985).
46. White, G. A., and Thorn, G. D. Structure-activity relationship
for carboxamide fungicides and succinic-dehydrogenase complexSUBSTRUCTURAL QSAR AND TOPOLOGICAL PHARMACOPHORES 255
ofCryptococcus laurentii and Ustilago maydis. Pestic. Biochem.
Physiol. 5: 380-395 (1975).
47. Dove, S., and Franke, R. Discriminant analysis and QSAR work.
In: Quantitative Structure-Activity Analysis (R. Franke and P.
Oehme, Eds.), Akademie-Verlag, Berlin, 1978.
48. Magee, P. S. A new approach to bioactive synthesis. In: Com-
puter-Assisted Drug Design (E. C. Olsen and R. E. Christo-
pherson, Eds.), ACS Symp. Ser. 112, American Chemical Society,
Washington, DC, 1979, pp. 319-340.
49. Enslein, K., and Craig, P. N. A toxicity estimation model. J.
Environ. Pathol. Toxicol. 2: 115-121 (1978).
50. Enslein, K., and Craig, P. N. Status Report on Development of
Predictive Models of Toxicological Endpoints. Genese Corp.,
Rochester, 1979.
51. Yuta, K., and Jurs, P. C. Computer-assisted structure-activity
studies ofchemical carcinogens. Aromatic amines. J. Med. Chem.
24: 241-251 (1981).
52. Chou, J. T., andJurs, P. C. Computer-assisted structure-activity
studies ofchemical carcinogens. AnN-nitroso compound data set.
J. Med. Chem. 22: 792-797 (1979).
53. Rekker, R. F. LD50values: aretheyabouttobecomepredictable?
TIPS 383-384 (1980).